{"name": "AVEO Pharmaceuticals",
 "permalink": "aveo-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/aveo-pharmaceuticals",
 "homepage_url": "http://www.aveopharma.com",
 "blog_url": "",
 "blog_feed_url": "http://www.aveooncology.com/for-media/",
 "twitter_username": "AVEOPharma",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2012,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "cancer, pharmaceuticals, kidney-cancer",
 "alias_list": "",
 "email_address": "",
 "phone_number": "(617) 299-5000",
 "description": "Treatment for Kidney Cancer",
 "created_at": "Tue Jul 28 21:16:31 UTC 2009",
 "updated_at": "Thu Mar 28 12:31:41 UTC 2013",
 "overview": "\u003Cp\u003EAVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO\u00e2\u20ac\u2122s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. \u003C/p\u003E\n\n\u003Cp\u003EThis approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       139],
      "assets/images/resized/0005/4525/54525v1-max-150x150.png"],
     [[230,
       214],
      "assets/images/resized/0005/4525/54525v1-max-250x250.png"],
     [[230,
       214],
      "assets/images/resized/0005/4525/54525v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Tuan",
      "last_name": "Ha-Ngoc",
      "permalink": "tuan-ha-ngoc",
      "image": null}},
   {"is_past": false,
    "title": "Chief Commercial Officer",
    "person":
     {"first_name": "Michael",
      "last_name": "P. Bailey",
      "permalink": "michael-p-bailey",
      "image": null}},
   {"is_past": false,
    "title": "VP Technical operations",
    "person":
     {"first_name": "Donna",
      "last_name": "M. Radzik",
      "permalink": "donna-m-radzik",
      "image": null}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Henri",
      "last_name": "A. Termeer",
      "permalink": "henri-a-termeer",
      "image": null}},
   {"is_past": true,
    "title": "CFO",
    "person":
     {"first_name": "Peter",
      "last_name": "Courossi",
      "permalink": "peter-courossi",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$45M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/aveo-grabs-20m-expanded-osi-collaboration/2009-07-21?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0",
    "source_description": "Aveo grabs $20M in expanded OSI collaboration ",
    "raised_amount": 20000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 7,
    "funded_day": 21,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.alacrastore.com/storecontent/Datamonitor_Mergers_and_Acquisitions-Hercules_Technology_Growth_Capital_provides_25_million_commitment_to_Aveo_Pharmaceuticals-2052-34174",
    "source_description": "Hercules Technology Growth Capital provides $25 million commitment to Aveo Pharmaceuticals",
    "raised_amount": 25000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 5,
    "funded_day": 28,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Hercules Technology Growth Capital",
         "permalink": "hercules-technology-growth",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0001/4495/14495v6-max-150x150.png"],
             [[250,
               86],
              "assets/images/resized/0001/4495/14495v6-max-250x250.png"],
             [[416,
               144],
              "assets/images/resized/0001/4495/14495v6-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "75 Sidney Street, 4th Floor",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": 42.3609606,
    "longitude": -71.1017618}],
 "milestones":
  [{"description": "AVEO files for $86.3M IPO",
    "stoned_year": 2009,
    "stoned_month": 12,
    "stoned_day": 17,
    "source_url": "http://www.masshightech.com/stories/2009/12/14/daily45-Aveo-Pharma-files-for-863M-IPO.html",
    "source_text": "",
    "source_description": "Aveo Pharma files for up to $86.3M IPO  ",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "Aveo Delays IPO",
    "stoned_year": 2010,
    "stoned_month": 3,
    "stoned_day": 11,
    "source_url": "http://www.fiercebiotech.com/story/aveo-pharma-delays-ipo-least-briefly/2010-03-11?utm_medium=rss\u0026utm_source=rss",
    "source_text": "Aveo Pharmaceuticals kept the biotech investment community on pins and needles this morning. The cancer drug developer was supposed to price its shares for a $105 million IPO yesterday, but reportedly pushed that back to today in the face of shareholder resistance to the share price.\r\nThe Wall Street Journal reported the resistance at the end of a lengthy piece today on the bullish investor response to Sensata, a venture-backed company that was able to hold on to its price range and trade higher on the first day--a first for the year.\r\nAfter a brief surge of hope that 2010 would see a big surge of biotech IPOs after a lengthy dry spell, the first developers to make it into the market all stumbled badly. Ironwood seriously overreached on its projected share price and Anthera raised $42 million in an IPO recently after chopping its share price in half.\r\n- here's the report from the Wall Street Journal, with the Aveo news mentioned at the end\r\n\r\n\r\nRead more: http://www.fiercebiotech.com/story/aveo-pharma-delays-ipo-least-briefly/2010-03-11?utm_medium=rss\u0026utm_source=rss#ixzz0jifXjO23",
    "source_description": "Aveo Pharma delays IPO, at least briefly ",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "AVEO Pharmaceuticals Announces $61 Million Private Placement",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 29,
    "source_url": "http://investor.aveopharma.com/phoenix.zhtml?c=219651\u0026p=irol-newsArticle\u0026ID=1489196\u0026highlight=",
    "source_text": "",
    "source_description": "AVEO Pharmaceuticals Announces $61 Million Private Placement",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "Aveo Pharmaceuticals Inc. is planning a private placement intended to bring in $61 million to the company.",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 29,
    "source_url": "http://www.masshightech.com/stories/2010/10/25/daily46-Aveo-to-offer-61M-stock-offering.html",
    "source_text": null,
    "source_description": "Aveo to offer $61M stock offering",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "has presented results on a pair of cancer treatments at the Symposium of the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research in Berlin, Germany.",
    "stoned_year": 2010,
    "stoned_month": 11,
    "stoned_day": 19,
    "source_url": "http://www.masshightech.com/stories/2010/11/15/daily61-AVEO-releases-data-on-cancer-drugs.html",
    "source_text": null,
    "source_description": "AVEO releases data on cancer drugs",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "Aveo nabs $1.4B deal with Astellas for Ph3 cancer drug\r\n",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 17,
    "source_url": "http://www.fiercebiotech.com/story/aveo-nabs-14b-deal-astellas-ph3-cancer-drug/2011-02-17?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Aveo nabs $1.4B deal with Astellas for Ph3 cancer drug",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "AVEO and Astellas Pharma Inc., of Tokyo, have formed a development and commercialization deal in which AVEO will bring in $125 million upfront and up to $1.3 billion in potential milestone payments",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 17,
    "source_url": "http://www.masshightech.com/stories/2011/02/14/daily42-AVEO-Astellas-form-potential-14B-drug-development-deal.html",
    "source_text": null,
    "source_description": "AVEO, Astellas form potential $1.4B drug development deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "it will receive an initial $15 million and up to $540 million in milestone payments in an exclusive license agreement with Centocor Ortho Biotech Inc.",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 31,
    "source_url": "http://www.masshightech.com/stories/2011/05/30/daily6-Aveo-deal-with-Centocor-could-be-sweetened-by-up-to-540M.html",
    "source_text": null,
    "source_description": "Aveo deal with Centocor could be sweetened by up to $540M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}},
   {"description": "Aveo Pharmaceuticals files for $100M stock offering",
    "stoned_year": 2011,
    "stoned_month": 6,
    "stoned_day": 15,
    "source_url": "http://www.masshightech.com/stories/2011/06/13/daily32-Aveo-Pharmaceuticals-files-for-100M-stock-offering.html",
    "source_text": "",
    "source_description": "Aveo Pharmaceuticals files for $100M stock offering",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AVEO Pharmaceuticals",
      "permalink": "aveo-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": 2010,
   "pub_month": 3,
   "pub_day": 11,
   "stock_symbol": "AVEO"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}